• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Fermi Inc. - Common Stock
Majestic Gold Corp
ProCap Acquisition Corp - Class A Ordinary Shares
Edit Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunoprecise Antibodies Ltd (TSV:IPA)

N/A UNCHANGED
Last Price Updated: 3:58 PM EST, Nov 25, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunoprecise Antibodies Ltd

News headline image
ImmunoPrecise Antibodies Ltd. Announces Voluntary Delisting from TSX Venture Exchange
November 22, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA’s Subsidiary Talem Therapeutics Licenses Antibodies for Three OmniChicken-Derived Programs
October 12, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
NIAID Confirms IPA’s PolyTope TATX-03 Neutralizing Activity Against the Currently Spreading SARS-CoV-2 Variant BA.2.75
September 14, 2022
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023
September 14, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2023 on September 14, 2022
September 08, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
Live Virus Assays at Ludwig-Maximilians-Universität München Confirm PolyTope’s Efficacy Against SARS-CoV-2 Variants Including BA.5
August 29, 2022
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
July 29, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2022 on July 29, 2022
July 26, 2022
From ImmunoPrecise Antibodies Ltd.
Via Business Wire
News headline image
Histopathology Data of Preclinical Repeated Dose Toxicity Study and ex vivo Human Tissue Cross-Reactivity (TCR) Analysis Support Safety of IPA’s PolyTope® TATX-03, a Synergistic Antibody Cocktail against SARS‑CoV‑2
July 12, 2022
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
April 20, 2022
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant
May 09, 2022
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
IPA Completes Acquisition of Belgian Technology Companies BioStrand, BioKey, and BioClue – Adding Artificial Intelligence-Driven Analytics to its Antibody Discovery Capabilities and Offerings
April 14, 2022
From ImmunoPrecise Antibodies
Via Business Wire
News headline image
Talem Therapeutics Announces Multi-Target Antibody Discovery Research Collaboration With Pierre Fabre
October 07, 2021
From ImmunoPrecise Antibodies Ltd
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap